Retatrutide vs Semaglutide: Research Compared

The short answer

Retatrutide and semaglutide are often discussed together because both belong to the broad class of incretin-related compounds, but they sit at very different points in their regulatory and developmental life. Semaglutide is a single-pathway glucagon-like peptide-1 (GLP-1) receptor agonist that is an approved, registered prescription medicine in Australia. Retatrutide, known in development literature as LY3437943, is an investigational triple receptor agonist that is not approved anywhere and remains in clinical trials.

The simplest way to frame the comparison is this. Semaglutide acts at one incretin receptor and is a marketed medicine. Retatrutide is designed to act at three receptors at once and is still experimental. This guide summarises those distinctions at an educational level without making any therapeutic, efficacy or dosing claims.

What retatrutide is

Retatrutide is a synthetic peptide assigned the development code LY3437943 by its developer, Eli Lilly. In the scientific literature it is most often described as a triple receptor agonist, meaning it is engineered to bind and activate three distinct receptors involved in metabolic signalling: the GLP-1 receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon receptor.

Retatrutide is an investigational compound. As of the research available for this guide, it has not been approved for use by any medicine regulator, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or the Australian Therapeutic Goods Administration (TGA). It does not appear on the Australian Register of Therapeutic Goods (ARTG) as an approved medicine. It is being evaluated in a Phase 3 clinical trial programme, which places it in a late stage of investigation but still short of regulatory approval.

How retatrutide is described in the literature

• An Eli Lilly investigational compound with the development code LY3437943
• A triple agonist targeting GLP-1, GIP and glucagon receptors
• Under evaluation in a Phase 3 trial programme at the time of writing
• Not approved by the FDA, EMA or TGA and not listed on the ARTG

What semaglutide is

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. Unlike retatrutide, semaglutide is an approved, registered medicine. It is marketed under brand names including Ozempic, Wegovy and Rybelsus, with the specific registered indications differing by brand and by country.

In Australia, semaglutide is a registered medicine on the ARTG and is classified as a Schedule 4 (Prescription Only) substance. This means it can lawfully be supplied for human use only on the prescription of an authorised Australian health practitioner. The approval of a brand onto the ARTG reflects that the regulator has assessed a dossier of data for a specific, defined use. Public records indicate semaglutide-containing products have held ARTG registration in Australia for several years.

The central distinction for this comparison is straightforward. Semaglutide is an approved registered medicine subject to prescription control. Retatrutide is an unapproved investigational compound. The two are therefore not equivalent in regulatory standing, regardless of any similarities in the broad biological pathways they engage.

Mechanism compared: triple versus single agonist

The incretin system refers to a group of gut-derived hormones that influence metabolic signalling. Two of the best studied are GLP-1 and GIP. Glucagon is a separate hormone with its own receptor and distinct roles in metabolism. Compounds in this research area are often categorised by how many of these receptors they are designed to activate.

Semaglutide is a single agonist. It is designed to act selectively at the GLP-1 receptor. This single-pathway design has been studied extensively and underpins its status as an approved medicine with a well-characterised profile within its registered uses.

Retatrutide is described as a triple agonist. It is engineered to engage three receptors simultaneously: GLP-1, GIP and glucagon. The research rationale for multi-receptor agonism is that combining signalling pathways may produce a different pharmacological profile from single-pathway activation. Whether that translates into any particular real-world outcome is precisely what clinical trials are designed to investigate, and such questions remain open while a compound is still experimental.

Receptor targets at a glance

• Semaglutide: one receptor, GLP-1 (single agonist)
• Retatrutide: three receptors, GLP-1, GIP and glucagon (triple agonist)
• Both engage incretin-related signalling, but by different designs
• Receptor count alone does not determine approval status or any outcome

Regulatory status compared

For anyone reading the literature in Australia, regulatory status is one of the most important differences between these two compounds, because it governs what may lawfully be supplied and for what purpose.

Semaglutide is a registered medicine on the ARTG and is a Schedule 4 (Prescription Only) substance. A registered medicine has been through the TGA assessment process for a defined indication, and Schedule 4 classification means lawful supply for human use requires a prescription from an authorised practitioner.

Retatrutide has no such approval. It is not registered on the ARTG, has not been approved by the TGA, FDA or EMA, and remains an investigational compound confined to research and clinical trial settings. Describing retatrutide as if it were an available therapy would misrepresent its status. It is studied, not approved.

What the research and trials show

Both compounds have been studied in structured clinical trial programmes. Clinical trials are organised in phases, moving from early safety evaluation through to larger, later-stage studies that examine defined endpoints in defined populations. The purpose of describing trial stage here is to indicate how far along the evidence-gathering process a compound is, not to promise any result.

Semaglutide has completed the development pathway required for regulatory approval in its registered uses, which is why it is a marketed medicine. Its clinical data has been assessed by regulators as part of that process.

Retatrutide has been investigated in earlier-phase studies and is reported to be in a Phase 3 trial programme. Trials of retatrutide have investigated metabolic endpoints, and the compound has been studied across several conditions in its development programme. Because it is still investigational, the body of evidence is being built and reviewed rather than settled. Specific figures reported in individual studies are research findings in defined trial populations and should not be read as outcomes any individual would obtain, nor as claims of any kind from NovaPeptides.

A compound being studied in late-phase trials indicates where it sits in the evidence process. It is not a statement that the compound is approved, safe for any individual, or available for human use.

What research use only means

Research use only is a specific designation. It means a compound is intended for laboratory and scientific investigation and is not supplied, labelled or intended for human or veterinary use. A research-use-only compound is not a medicine, is not dispensed against a prescription, and carries no therapeutic claims.

This framing matters for both compounds discussed here. Semaglutide as a medicine is a separate, regulated category supplied through pharmacies on prescription. A research-grade peptide, by contrast, exists for laboratory work and is handled by qualified researchers under appropriate controls. Retatrutide, being investigational, is only legitimately encountered in research or clinical trial contexts rather than as a consumer product.

Research use only in practice

• Intended for laboratory and scientific research, not human or veterinary use
• Not a medicine and not supplied against a prescription
• Carries no therapeutic, efficacy or dosing claims
• Handled by qualified researchers under appropriate controls

How NovaPeptides supplies research compounds

NovaPeptides supplies peptides strictly as research compounds for laboratory research use only. Products are not supplied for human consumption, are not medicines, and are not offered with any therapeutic or dosing guidance. Nothing in this guide should be read as encouragement to use any compound in humans.

Because semaglutide is a prescription-only registered medicine and retatrutide is an unapproved investigational compound, neither is appropriate to discuss in terms of personal use. Researchers remain responsible for complying with all applicable Australian laws, institutional requirements and handling standards that apply to their work.

Frequently asked questions